F&V Capital Management LLC Sells 1,375 Shares of Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

F&V Capital Management LLC cut its stake in Merck & Co., Inc. (NYSE:MRK) by 2.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 54,863 shares of the company’s stock after selling 1,375 shares during the period. Merck & Co., Inc. accounts for approximately 2.7% of F&V Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding. F&V Capital Management LLC’s holdings in Merck & Co., Inc. were worth $4,990,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of MRK. BancorpSouth Bank increased its position in Merck & Co., Inc. by 3.1% during the third quarter. BancorpSouth Bank now owns 50,676 shares of the company’s stock worth $4,266,000 after acquiring an additional 1,538 shares during the period. Lehman & Derafelo Financial Resources LLC increased its position in Merck & Co., Inc. by 5.1% during the second quarter. Lehman & Derafelo Financial Resources LLC now owns 51,175 shares of the company’s stock worth $4,381,000 after acquiring an additional 2,502 shares during the period. Nomura Holdings Inc. increased its position in Merck & Co., Inc. by 260.4% during the third quarter. Nomura Holdings Inc. now owns 801,905 shares of the company’s stock worth $67,143,000 after acquiring an additional 579,388 shares during the period. Pictet Asset Management Ltd. increased its position in Merck & Co., Inc. by 5.2% during the third quarter. Pictet Asset Management Ltd. now owns 2,519,127 shares of the company’s stock worth $212,060,000 after acquiring an additional 123,617 shares during the period. Finally, Ashburton Jersey Ltd increased its position in Merck & Co., Inc. by 0.4% during the third quarter. Ashburton Jersey Ltd now owns 210,924 shares of the company’s stock worth $17,756,000 after acquiring an additional 750 shares during the period. 74.50% of the stock is currently owned by institutional investors.

In other news, EVP Julie L. Gerberding sold 102,073 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $89.34, for a total value of $9,119,201.82. Following the sale, the executive vice president now directly owns 106,099 shares in the company, valued at approximately $9,478,884.66. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.27% of the stock is owned by company insiders.

MRK stock opened at $91.54 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84. Merck & Co., Inc. has a 12 month low of $72.05 and a 12 month high of $92.64. The firm has a market cap of $228.96 billion, a P/E ratio of 21.09, a P/E/G ratio of 1.80 and a beta of 0.52. The company’s 50-day moving average price is $89.80 and its two-hundred day moving average price is $85.55.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The firm had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. During the same period last year, the firm earned $1.19 EPS. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Equities analysts predict that Merck & Co., Inc. will post 5.15 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th were issued a $0.61 dividend. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 annualized dividend and a yield of 2.67%. The ex-dividend date of this dividend was Friday, December 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 56.22%.

MRK has been the topic of a number of recent research reports. Bank of America initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price target on the stock. Mizuho reaffirmed a “buy” rating and set a $100.00 price target on shares of Merck & Co., Inc. in a research report on Monday, January 6th. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. Finally, ValuEngine lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $95.69.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: S&P 500 Index

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.